Background: The Marburg virus (MARV) is the causative agent of Marburg virus disease (MVD). This filovirus first appeared in 1967 and has since caused several outbreaks with case fatality rates between 23% and 90%. The earliest cases of MVD are thought to be caused by exposure to an infected animal, either a reservoir host (some bat species, e.g., Rousettus aegyptiacus) or a spill-over host, such as non-human primates. The virus is spread between people by direct contact with blood or other bodily fluids (including saliva, sweat, faeces, urine, tears, and breast milk) from infected individuals. Despite the high fatality rate, the Marburg virus has no vaccine or drug treatment. Recent outbreaks of the virus in 2023 in Tanzania and Equatorial Guinea have reignited the need to develop effective therapeutics, especially in the wake of the COVID-19 pandemic. Purpose: This review seeks to highlight the drug discovery efforts aimed at developing vaccines or possible treatments as potential therapeutics. Several existing antiviral agents are being probed, and vaccines are in pre-clinical and clinical stages. Natural products are also an important source of possible drugs or lead compounds and when coupled with computational techniques, these strategies offer possible therapeutics for the Marburg virus, especially in Africa, which has a high disease burden. Methods: Using the search engines Google Scholar and PubMed; keywords e.g. Marburg virus, Marburg treatments, Marburg virus drug discovery were utilized. Several results were yielded, and articles published in recent years were accepted into the final list.Results and Conclusion: This study shows there is a growing interest in therapeutics for the Marburg virus, especially with the recent outbreaks and pandemic preparedness. Initiatives that to support vaccine development and access like the MARVAC consort time are critical to fighting this public health threat.
References
[1]
Kuhn, J.H., Adachi, T., Adhikari, N.K.J., et al.(2019) New Filovirus Disease Classification and Nomenclature. Nature Reviews Microbiology, 17, 261-263. https://doi.org/10.1038/s41579-019-0187-4
[2]
Shifflett, K. and Marzi, A. (2019) Marburg Virus Pathogenesis-Differences and Similarities in Humans and Animal Models. Virology Journal, 16, Article No. 165. https://doi.org/10.1186/s12985-019-1272-z
[3]
Slenczka, W. and Klenk, H.D. (2007) Forty Years of Marburg Virus. The Journal of Infectious Diseases, 196, 131-135. https://doi.org/10.1086/520551
[4]
Hofmann, H. and Kunz, C. (1971) Cultivation of the Marburg Virus (Rhabdovirus simiae) in Cell Cultures. In: Martini, G.A. and Siegert, R., Eds., Marburg Virus Disease, Springer, Berlin, 112-116. https://doi.org/10.1007/978-3-662-01593-3_15
[5]
Brauburger, K., Hume, A.J., Mühlberger, E. and Olejnik, J. (2012) Forty-Five Years of Marburg Virus Research. Viruses, 4, 1878-1927. https://doi.org/10.3390/v4101878
[6]
Bray, M. (2001) The Role of the Type I Interferon Response in the Resistance of Mice to Filovirus Infection. Journal of General Virology, 82, 1365-1373. https://doi.org/10.1099/0022-1317-82-6-1365
[7]
Sah, R., Mohanty, A., Reda, A., Siddiq, A., Mohapatra, R.K. and Dhama, K. (2022) Marburg Virus Re-Emerged in 2022: Recently Detected in Ghana, Another Zoonotic Pathogen Coming up Amid Rising Cases of Monkeypox and Ongoing COVID-19 Pandemic-Global Health Concerns and Counteracting Measures. Veterinary Quarterly, 42, 167-171. https://doi.org/10.1080/01652176.2022.2116501
[8]
Manohar, M.P.M., Lee, V.J., Odunukwe, E.U.C., Singh, P.K., Mpofu, B.S. and Oxley, C. (2023) Advancements in Marburg (MARV) Virus Vaccine Research with Its Recent Reemergence in Equatorial Guinea and Tanzania: A Scoping Review. Cureus, 15, e42014. https://doi.org/10.7759/cureus.42014
[9]
Rougeron, V., Feldmann, H., Grard, G., Becker, S. and Leroy, E.M. (2015) Ebola and Marburg Haemorrhagic Fever. Journal of Clinical Virology, 64, 111-119. https://doi.org/10.1016/j.jcv.2015.01.014
[10]
Falasca, L., Agrati, C., Petrosillo, N., et al. (2015) Molecular Mechanisms of Ebola Virus Pathogenesis: Focus on Cell Death. Cell Death and Differentiation, 22, 1250-1259. https://doi.org/10.1038/cdd.2015.67
[11]
Hoffmann, M., Crone, L., Dietzel, E., et al. (2017) A Polymorphism within the Internal Fusion Loop of the Ebola Virus Glycoprotein Modulates Host Cell Entry. Journal of Virology, 91, e00177. https://doi.org/10.1128/JVI.00177-17
[12]
Gruss, C., Wetzel, E., Baack, M., Mock, U. and Knippers, R. (1988) High-Affinity SV40 T-Antigen Binding Sites in the Human Genome. Virology, 167, 349-360. https://doi.org/10.1016/S0042-6822(88)90095-5
[13]
Carette, J.E., Raaben, M., Wong, A.C., et al. (2011) Ebola Virus Entry Requires the Cholesterol Transporter Niemann-Pick C1. Nature, 477, 340-343. https://doi.org/10.1038/nature10348
[14]
Elsheikh, R., Makram, A.M., Selim, H., et al. (2023) Reemergence of Marburgvirus disease: Update on Current Control and Prevention Measures and Review of the Literature. Reviews in Medical Virology, 33, e2461. https://doi.org/10.1002/rmv.2461
[15]
Mehedi, M., Groseth, A., Feldmann, H. and Ebihara, H. (2011) Clinical Aspects of Marburg Hemorrhagic Fever. Future Virology, 6, 1091-1106. https://doi.org/10.2217/fvl.11.79
[16]
Bausch, D.G., Borchert, M., Grein, T., et al. (2003) Risk Factors for Marburg Hemorrhagic Fever, Democratic Republic of the Congo. Emerging Infectious Diseases, 9, 1531-1537. https://doi.org/10.3201/eid0912.030355
[17]
Hunter, N. and Rathish, B. (2023) Marburg Fever. StatPearls, Treasure Island. https://www.ncbi.nlm.nih.gov/books/NBK578176/
[18]
Julander, J.G., Demarest, J.F., Taylor, R., et al. (2021) An Update on the Progress of Galidesivir (BCX4430), A Broad-Spectrum Antiviral. Antiviral Research, 195, Article 105180. https://doi.org/10.1016/j.antiviral.2021.105180
[19]
Warren, T.K., Wells, J., Panchal, R.G., et al. (2014) Protection Against Filovirus Diseases by a Novel Broad-Spectrum Nucleoside Analogue BCX4430. Nature, 508, 402-405. https://doi.org/10.1038/nature13027
[20]
Agrawal, U., Raju, R. and Udwadia, Z.F. (2020) Favipiravir: A New and Emerging Antiviral Option in COVID-19. Medical Journal Armed Forces India, 76, 370-376. https://doi.org/10.1016/j.mjafi.2020.08.004
[21]
Bixler, S.L., Bocan, T.M., Wells, J., et al. (2018) Efficacy of Favipiravir (T-705) in Nonhuman Primates Infected with Ebola Virus or Marburg Virus. Antiviral Research, 151, 97-104. https://doi.org/10.1016/j.antiviral.2017.12.021
[22]
Porter, D.P., Weidner, J.M., Gomba, L., et al.(2020) Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected with Marburg Virus. The Journal of Infectious Diseases, 222, 1894-1901. https://doi.org/10.1093/infdis/jiaa290
[23]
Valmas, C., Grosch, M.N., Schümann, M., et al.(2010) Marburg Virus Evades Interferon Responses by a Mechanism Distinct from Ebola Virus. PLOS Pathogens, 6, e1000721. https://doi.org/10.1371/journal.ppat.1000721
[24]
Luthra, P., Anantpadma, M., De, S., et al. (2020) High-Throughput Screening Assay to Identify Small Molecule Inhibitors of Marburg Virus VP40 Protein. ACS Infectious Diseases, 6, 2783-2799. https://doi.org/10.1021/acsinfecdis.0c00512
[25]
Kortepeter, M.G., Dierberg, K., Shenoy, E.S. and Cieslak, T.J. (2020) Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID-19. The COVID-19 Resource Centre Is Hosted on Elsevier Connect, The Company’s Public News and Information.
[26]
Mire, C.E., Geisbert, J.B., Borisevich, V., et al. (2017) Therapeutic Treatment of Marburg and Ravn Virus Infection in Nonhuman Primates with a Human Monoclonal Antibody. Science Translational Medicine, 9, eaai8711. https://doi.org/10.1126/scitranslmed.aai8711
[27]
Cross, R.W., Longini, I.M., Becker, S., et al. (2022) An Introduction to the Marburg Virus Vaccine Consortium, MARVAC. PLOS Pathogens, 18, e1010805. https://doi.org/10.1371/journal.ppat.1010805
[28]
Hamer, M.J., Houser, K.V., Hofstetter, A.R., et al. (2023) Safety, Tolerability, and Immunogenicity of the Chimpanzee Adenovirus Type 3-Vectored Marburg Virus (cAd3-Marburg) Vaccine in Healthy Adults in the USA: A First-in-Human, Phase 1, Open-Label, Dose-Escalation Trial. The Lancet, 401, 294-302. https://doi.org/10.1016/S0140-6736(22)02400-X
[29]
Mire, C.E., Geisbert, J.B., Agans, K.N., et al. (2014) Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates. PLOS ONE, 9, e94355. https://doi.org/10.1371/journal.pone.0094355
[30]
Marzi, A., Menicucci, A.R., Engelmann, F., et al. (2019) Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation. Frontiers in Immunology, 9, Article 3071. https://doi.org/10.3389/fimmu.2018.03071
[31]
Newman, D.J., Cragg, G.M. and Snader, K.M. (2000) The Influence of Natural Products upon Drugdiscovery. Natural Product Reports, 17, 215-234. https://doi.org/10.1039/a902202c
[32]
Rasul, A., Millimouno, F.M., Eltayb, W.A., Ali, M., Li, J. and Li, X. (2013) Pinocembrin: A Novel Natural Compound with Versatile Pharmacological and Biological Activities. BioMed Research International, 2013, Article ID: 379850. https://doi.org/10.1155/2013/379850
[33]
Akash, S., Islam, R., Rahman, M., Hossain, S. and Azad, A.K. (2023) Investigation of the New Inhibitors by Modified Derivatives of Pinocembrin for the Treatment of Monkeypox and Marburg Virus with Different Computational Approaches. Biointerface Research in Applied Chemistry, 13, Article 534.
[34]
Surabhi, S. and Singh, B. (2018) Computer Aided Drug Design: An Overview. Journal of Drug Delivery and Therapeutics, 8, 504-509. https://doi.org/10.22270/jddt.v8i5.1894
[35]
Daina, A., Blatter, M.-C., Gerritsen, V.B., et al.(2017) Drug Design Workshop: A Web-Based Educational Tool to Introduce Computer-Aided Drug Design to the General Public.Journal of Chemical Education, 94, 335-344. https://doi.org/10.1021/acs.jchemed.6b00596
[36]
Quazi, S., Malik, J., Suman, K.S., Capuzo, A.M. and Haider, Z. (2021) Discovery of Potential Drug-Like Compounds against Viral Protein (VP40) of Marburg Virus Using Pharmacophoric Based Virtualscreening from ZINC Database. https://doi.org/10.1101/2021.05.13.444037
[37]
Quazi, S., Gavas, S., Malik, J.A., Suman, K.S. and Haider, Z. (2021) In-Silico Pharmacophore and Molecular Docking Based Drug Discovery against Marburg Virus’s Viral Protein 35; A Potent of MAVD. bioRxiv Preprint. https://doi.org/10.1101/2021.07.01.450693
